Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $7.4250 (-5.23%) ($7.3250 - $7.4250) on Thu. Feb. 9, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.18% (three month average) | RSI | 72 | Latest Price | $7.4250(-5.23%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA declines -1.7% a day on average for past five trading days. | Weekly Trend | IOVA advances 3.9% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) XBI(50%) IBB(37%) IWC(29%) ARKG(28%) ARKK(26%) | Factors Impacting IOVA price | IOVA will decline at least -2.59% in a week (0% probabilities). VIXM(-13%) EDOC(-13%) BND(-10%) UUP(-9%) XLP(-8%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.59% (StdDev 5.18%) | Hourly BBV | -2.2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $7.43 | 5 Day Moving Average | $7.94(-6.49%) | 10 Day Moving Average | $7.97(-6.84%) | 20 Day Moving Average | $7.43(-0.07%) | To recent high | -16.4% | To recent low | 32.4% | Market Cap | $1.087b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |